Huntingdon Life Sciences considers close of Harlan Laboratories in Switzerland

Huntingdon Life Sciences (HLS) is considering the cessation of the majority of its contract research operations at Harlan Laboratories Switzerland.

 

In May of this year, when HLS acquired the Harlan business, HLS indicated intent to create a leading, dynamic company that was financially strong and dedicated to providing the products and services our customers need on a global scale.

 

For the last 4 months the company have pursued that objective with a rigorous analysis of the joint business and the development of a comprehensive integration program. A major part of this process has been to complete a thorough capacity analysis to identify how it can provide the products and services our customers want at competitive prices. In the course of this analysis it has become apparent that the Swiss Contract Research Services business will continue to face serious profitability challenges, based on business volume levels, current market pricing and operating costs. Thus, the company entered into consultation with the staff to consider the potential closure of some or all of the facilities.

 

Whatever actions HLS ultimately take, the company’s aim is to safeguard and enhance the financial strength. This will allow HLS to develop and further invest in innovation enabling it to be a vital research provider for the future.

 

HLS reassure that the company are not considering the cessation of activities at any further facilities. In addition, Research Models and Services business, supplying animals, services, diets and bedding to Swiss customers, will continue as normal. With approximately 3500 staff in 37 sites across North America, Europe, the Middle East and Asia, HLS will continue to offer a wealth of expertise and capabilities, and full range of products and services.